Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Stock analysts at began coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of Aeterna Zentaris in a research note on Tuesday, March 28th.

Aeterna Zentaris Stock Performance

Shares of AEZS stock opened at $2.92 on Friday. Aeterna Zentaris has a 52-week low of $2.32 and a 52-week high of $8.63. The firm has a market capitalization of $14.18 million, a P/E ratio of -0.58 and a beta of 1.38. The stock has a 50 day moving average price of $2.85 and a 200 day moving average price of $3.35.

Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) last announced its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.09. The company had revenue of $2.49 million during the quarter, compared to analysts’ expectations of $1.06 million. As a group, sell-side analysts forecast that Aeterna Zentaris will post -3.54 EPS for the current year.

About Aeterna Zentaris

(Get Rating)

Æterna Zentaris, Inc is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Featured Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.